Literature DB >> 24242758

STAT4 is critical for immunity but not for antileishmanial activity of antimonials in experimental visceral leishmaniasis.

Steve Oghumu1, Gaurav Gupta, Heidi M Snider, Sanjay Varikuti, César A Terrazas, Tracey L Papenfuss, Mark H Kaplan, Abhay R Satoskar.   

Abstract

We and others have previously shown that IL-12 is indispensable for immunity and is required for the optimal antiparasitic activity of antimonials in experimental visceral leishmaniasis caused by Leishmania donovani. Here we investigated the role of STAT4 in immunity against L. donovani using STAT4 knockout mice and also determined the effect of STAT4 deficiency in response to antimonial therapy. Upon infection with L. donovani, stat4⁻/⁻ BALB/c and C57BL/6 mice showed enhanced susceptibility to Leishmania during late time points of infection which was associated with a marked reduction in Th1 responses and hepatic immunopathology. Interestingly, these defects in Th1 responses in stat4⁻/⁻ did not impair the antimonial chemotherapy as both stat4⁻/⁻ and WT mice showed comparable levels of parasite clearance from the liver and spleen. These findings highlight the role of STAT4 in immunity to L. donovani infection and also provide evidence that STAT4 is dispensable for antimonial-based chemotherapy.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  IFN-γ; IL-12; Leishmania donovani; STAT4 chemotherapy; Sodium stibogluconate

Mesh:

Substances:

Year:  2013        PMID: 24242758      PMCID: PMC3946220          DOI: 10.1002/eji.201343477

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  39 in total

1.  A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.

Authors:  H J Ahn; S Maruo; M Tomura; J Mu; T Hamaoka; K Nakanishi; S Clark; M Kurimoto; H Okamura; H Fujiwara
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

2.  Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells.

Authors:  W E Thierfelder; J M van Deursen; K Yamamoto; R A Tripp; S R Sarawar; R T Carson; M Y Sangster; D A Vignali; P C Doherty; G C Grosveld; J N Ihle
Journal:  Nature       Date:  1996-07-11       Impact factor: 49.962

3.  Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis.

Authors:  H W Murray
Journal:  J Infect Dis       Date:  1997-06       Impact factor: 5.226

4.  Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice.

Authors:  M H Kaplan; Y L Sun; T Hoey; M J Grusby
Journal:  Nature       Date:  1996-07-11       Impact factor: 49.962

5.  Induction of macrophage antiprotozoal activity by monocyte chemotactic and activating factor.

Authors:  S B Mannheimer; J Hariprashad; M Y Stoeckle; H W Murray
Journal:  FEMS Immunol Med Microbiol       Date:  1996-05

6.  Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.

Authors:  H W Murray; J Hariprashad; R E Fichtl
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  IFN-gamma induces IL-12 mRNA expression by a murine macrophage cell line, J774.

Authors:  A Yoshida; Y Koide; M Uchijima; T O Yoshida
Journal:  Biochem Biophys Res Commun       Date:  1994-02-15       Impact factor: 3.575

8.  Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.

Authors:  R Bonecchi; G Bianchi; P P Bordignon; D D'Ambrosio; R Lang; A Borsatti; S Sozzani; P Allavena; P A Gray; A Mantovani; F Sinigaglia
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

9.  Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice.

Authors:  B Lu; B J Rutledge; L Gu; J Fiorillo; N W Lukacs; S L Kunkel; R North; C Gerard; B J Rollins
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

10.  Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice.

Authors:  A P Taylor; H W Murray
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

View more
  11 in total

1.  The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Sanjay Varikuti; Greta Volpedo; Noushin Saljoughian; Omar M Hamza; Gregory Halsey; Nathan M Ryan; Bren E Sedmak; Gabriella R Seidler; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

2.  STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity.

Authors:  Sanjay Varikuti; Steve Oghumu; Gayathri Natarajan; Jennifer Kimble; Rachel H Sperling; Ellen Moretti; Mark H Kaplan; Abhay R Satoskar
Journal:  Int Immunol       Date:  2016-08-30       Impact factor: 4.823

3.  MicroRNA 155 Contributes to Host Immunity against Leishmania donovani but Is Not Essential for Resolution of Infection.

Authors:  Sanjay Varikuti; Gayathri Natarajan; Greta Volpedo; Bhawana Singh; Omar Hamza; Gretchen V Messick; Mireia Guerau-de-Arellano; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

4.  Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.

Authors:  Henry W Murray; Andrew D Luster; Hua Zheng; Xiaojing Ma
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

5.  Transgenic T cell-specific expression of CXCR3 enhances splenic and hepatic T cell accumulation but does not affect the outcome of visceral leishmaniasis.

Authors:  Sanjay Varikuti; Gayathri Natarajan; Steve Oghumu; Rachel H Sperling; Ellen Moretti; James Stock; Tracey L Papenfuss; Abhay R Satoskar
Journal:  Cell Immunol       Date:  2016-09-06       Impact factor: 4.868

6.  IL-17A promotes susceptibility during experimental visceral leishmaniasis caused by Leishmania donovani.

Authors:  Cesar Terrazas; Sanjay Varikuti; Jennifer Kimble; Ellen Moretti; Prosper N Boyaka; Abhay R Satoskar
Journal:  FASEB J       Date:  2015-11-18       Impact factor: 5.191

7.  Pentalinonsterol, a Phytosterol from Pentalinon andrieuxii, is Immunomodulatory through Phospholipase A2 in Macrophages toward its Antileishmanial Action.

Authors:  Sanjay Varikuti; Andrew B Shelton; Sainath R Kotha; Travis Gurney; Gaurav Gupta; Thomas J Hund; James R Fuchs; A Douglas Kinghorn; Nidhi Srivastava; Abhay R Satoskar; Narasimham L Parinandi
Journal:  Cell Biochem Biophys       Date:  2021-08-13       Impact factor: 2.194

Review 8.  Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Front Immunol       Date:  2014-06-26       Impact factor: 7.561

9.  Leishmania infantum Parasites Subvert the Host Inflammatory Response through the Adenosine A2A Receptor to Promote the Establishment of Infection.

Authors:  Mikhael H F Lima; Lais A Sacramento; Gustavo F S Quirino; Marcela D Ferreira; Luciana Benevides; Alynne K M Santana; Fernando Q Cunha; Roque P Almeida; João S Silva; Vanessa Carregaro
Journal:  Front Immunol       Date:  2017-07-20       Impact factor: 7.561

Review 10.  Regulation of immunity during visceral Leishmania infection.

Authors:  Vasco Rodrigues; Anabela Cordeiro-da-Silva; Mireille Laforge; Ricardo Silvestre; Jérôme Estaquier
Journal:  Parasit Vectors       Date:  2016-03-01       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.